Last reviewed · How we verify
Saccharomyces boulardii
At a glance
| Generic name | Saccharomyces boulardii |
|---|---|
| Also known as | Probiotics, Floratil, Saccaromyces boulardii, Precosa, Perenterol® Forte |
| Sponsor | RESnTEC, Institute of Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Probiotics, Antibiotics and the Post-Antibiotic Microbiota (NA)
- Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation (NA)
- Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function (EARLY_PHASE1)
- Effect of Saccharomyces Boulardii CNCM I-745 (Sb) on Bloody Diarrhea in Children. A Double Blind, Randomized, Controlled Study ( Sb192-SUH ) (PHASE4)
- Effect of Probiotics on Relapsing-Remitting Multiple Sclerosis (NA)
- Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study) (PHASE4)
- Combined Rehabilitation and Nutritional Support vs. Standard Care in In-Hospital Endocarditis Treatment (NA)
- Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saccharomyces boulardii CI brief — competitive landscape report
- Saccharomyces boulardii updates RSS · CI watch RSS
- RESnTEC, Institute of Research portfolio CI